We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
- Cancer/Oncology
-
2. Artificial intelligence in precision medicine
- Dr. Michael P. Menden
-
3. CAR-T and TCR-T cellular immunotherapies in oncology
- Prof. Sebastian Kobold
-
4. Precision cancer medicine: development and future
- Prof. Maurie Markman
-
5. Pediatric cancer testing
- Prof. Joshua Schiffman
- Neurology/Neuroscience
-
8. PANDAS: a potential link between group A streptococcal infections and neurological disorders
- Prof. P. Patrick Cleary
-
9. Characterizing barriers to care in migraine
- Prof. Dawn C. Buse
- Cardiovascular
-
10. Hypertrophic cardiomyopathy: therapies and treatments
- Prof. Srihari Naidu
- Respiratory Diseases
-
12. Predicting asthma exacerbations using machine learning models
- Dr. Nestor Molfino
- Immunology & Inflammation
-
13. Antiphospholipid syndrome and Lupus
- Prof. Graham Hughes
-
14. Opposition to vaccination: a transatlantic discussion
- Prof. Jonathan Temte
- Infectious Diseases/Microbiology
-
15. Combating the HIV epidemic
- Prof. William Blattner
-
16. Monkeypox: etiopathogenesis, prevention, and treatments
- Dr. Dennis Hruby
- Clinical Practice
-
18. Prescribing medications to children - a GP’s view
- Dr. Amanda Simmons
-
19. MAPS: the business of medical affairs
- Dr. Danie du Plessis
-
20. Kidney xenotransplantation
- Dr. Douglas J. Anderson
-
21. Epigenetic pharmaceuticals used in the clinic
- Dr. Thomas Paul
-
22. Elective caesarean sections from an evolutionary perspective
- Prof. Wenda Trevathan
Topics Covered
- Amyloid build-up and the importance of early diagnosis
- The potential of inhibiting vs. clearing amyloid aggregation
- Different potential therapeutic approaches designed for different stages of Alzheimer’s
- The future of therapies targeting amyloid deposition
Biography
John Hardy is a geneticist and molecular biologist whose research interests focus on neurological disease. Dr. Hardy received his B.Sc. (Hons) degree from the University of Leeds, UK (1976) and his Ph.D. from Imperial College, London, UK where he studied dopamine and amino acid neuropharmacology. Dr. Hardy received his postdoctoral training at the MRC Neuropathogenesis Unit in Newcastle upon Tyne, UK and then further postdoctoral work at the Swedish Brain Bank in Umeå, Sweden where he started to work on Alzheimer’s disease. He became Assistant Professor of Biochemistry at St. Mary’s Hospital, Imperial College, London in 1985 and initiated genetic studies of Alzheimer’s disease whilst there. He was appointed Associate Professor in 1989 and then took the Pfeiffer Endowed Chair of Alzheimer’s Research at the University of South Florida, in Tampa in 1992. In 1996 he moved to the Mayo Clinic in Jacksonville, Florida, as Consultant and Professor of Neuroscience. He became Chair of Neuroscience in 2000 and moved to NIA as Chief of the Laboratory of Neurogenetics in 2001. He won the MetLife, the Allied Signal and the Potamkin Prize for his work in describing the first genetic mutations, in the amyloid gene in Alzheimer’s disease, in 1991. He was Head of the Neurogenetics Section, National Institute of Ageing, Bethesda, USA and in 2007 took up the Chair of Molecular Biology of Neurological Disease at the UCL Institute of Neurology. With over 23,000 citations, Prof Hardy is the most cited Alzheimer's disease researcher in the UK (5th internationally). In recognition of his exceptional contributions to science, he was elected a Fellow of the Royal Society in 2009. In 2016 Prof Hardy received the Breakthrough Prize in Life Sciences for his research on the cause of early-onset Alzheimer’s disease.
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Hardy, J. (2018, April 1). Current directions in the prevention and treatment of Alzheimer’s disease [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 19, 2026, from https://doi.org/10.69645/VBTY5256.Export Citation (RIS)
Publication History
- Published on April 1, 2018
Financial Disclosures
- Prof. John Hardy, Consultant: Eisai Speaker's Bureau: Eli Lily Grant/Research Support (Principal Investiqator): MRC/Wellcome Trust